Conception

Conception is a private, pre-revenue biotech pioneering in-vitro gametogenesis (IVG) to generate human eggs from stem cells. Its platform integrates developmental biology, 3D organoid engineering, and computational automation to recreate the complex process of egg development in the lab. The company is targeting significant unmet needs in fertility, including age-related decline in egg quality and quantity, as well as medical infertility, positioning itself at the forefront of a potentially transformative reproductive technology. Conception is in the pre-clinical research and development stage, building its platform and advancing towards a future clinical therapy.

Integrated platform combining stem cell biology (iPSC reprogramming and differentiation), 3D ovarian tissue engineering (follicle organoids), and computational biology (gene network mapping, high-throughput screening, computer vision) to achieve in-vitro gametogenesis (IVG) for the production of human oocytes.

Conception operates in the emerging and highly competitive field of in-vitro gametogenesis. It faces competition from other well-funded private biotechs (e.g., Ivy Natal, which is also working on IVG) and leading academic labs worldwide. The competitive edge will be determined by who first achieves robust, scalable, and clinically translatable differentiation protocols and successfully navigates the regulatory process.